187 related articles for article (PubMed ID: 17762578)
21. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
22. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
23. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
24. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
25. Development of antiangiogenic therapies for ovarian cancer.
Markowska A; Lubin J; Madry R; Markowska J
Eur J Gynaecol Oncol; 2013; 34(4):303-6. PubMed ID: 24020134
[TBL] [Abstract][Full Text] [Related]
26. Experience with bevacizumab in the management of epithelial ovarian cancer.
Burger RA
J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
[TBL] [Abstract][Full Text] [Related]
27. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
28. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
29. Novel antiangiogenic therapies in ovarian cancer.
Stuckey A; Dizon DS
Womens Health (Lond); 2012 Jul; 8(4):447-53. PubMed ID: 22757735
[TBL] [Abstract][Full Text] [Related]
30. The use of bevacizumab in the management of ovarian cancer: an argument for single-agent rather than combination therapy.
Markman M
Ann Oncol; 2011 Dec; 22 Suppl 8():viii69-viii71. PubMed ID: 22180406
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic therapies in early-stage breast cancer.
Derleth C; Mayer IA
Clin Breast Cancer; 2010; 10 Suppl 1(Suppl 1):E23-31. PubMed ID: 20587404
[TBL] [Abstract][Full Text] [Related]
32. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
33. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives.
Colombo N; Conte PF; Pignata S; Raspagliesi F; Scambia G
Crit Rev Oncol Hematol; 2016 Jan; 97():335-48. PubMed ID: 26555461
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab in the treatment of ovarian cancer.
Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
[TBL] [Abstract][Full Text] [Related]
36. Angiogenesis inhibitors in the management of breast cancer.
Bossung V; Harbeck N
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):79-86. PubMed ID: 19952746
[TBL] [Abstract][Full Text] [Related]
37. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
38. Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
Chelariu-Raicu A; Coleman RL; Sood AK
Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365748
[TBL] [Abstract][Full Text] [Related]
39. Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.
Holtz DO; Krafty RT; Mohamed-Hadley A; Zhang L; Alagkiozidis I; Leiby B; Guo W; Gimotty PA; Coukos G
J Transl Med; 2008 Jan; 6():2. PubMed ID: 18182107
[TBL] [Abstract][Full Text] [Related]
40. Antiangiogenic drugs in ovarian cancer.
Markman M
Expert Opin Pharmacother; 2009 Oct; 10(14):2269-77. PubMed ID: 19671017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
